Metastatic Ureter Urothelial Carcinoma Recruiting Phase 2 Trials for Atezolizumab (DB11595)

IndicationStatusPhase
DBCOND0110110 (Metastatic Ureter Urothelial Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03513952Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaTreatment